Skip to main content

Table 1 (abstract P70). Treatment-emergent adverse events reported by 1.5% or more patients in any galcanezumab dose-group.

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

   Galcanezumab
Event Placebo
N=1451
n (%)
120-mg
N=705
n (%)
240-mg
N=730
n (%)
Combined N=1435
n (%)
Injection site pain 138 (9.5) 71 (10.1) 85 (11.6) 156 (10.9)
Nasopharyngitis 94 (6.5) 52 (7.4) 31 (4.3) 83 (5.8)
Upper respiratory tract infection 60 (4.1) 31 (4.4) 36 (4.9) 67 (4.7)
Injection site reaction 14 (1.0) 22 (3.1) 45 (6.2) 67 (4.7)
Dizziness 41 (2.8) 20 (2.8) 20 (2.7) 40 (2.8)
Injection site erythema 20 (1.4) 20 (2.8) 29 (4.0) 49 (3.4)
Sinusitis 31 (2.1) 20 (2.8) 19 (2.6) 39 (2.7)
Urinary tract infection 33 (2.3) 19 (2.7) 18 (2.5) 37 (2.6)
Fatigue 34 (2.4) 17 (2.4) 16 (2.2) 33 (2.3)
Injection site pruritus 2 (0.1) 15 (2.1) 24 (3.3) 39 (2.7)
Neck pain 21 (1.5) 15 (2.1) 6 (0.8) 21 (1.5)
Abdominal pain 24 (1.7) 13 (1.8) 6 (0.8) 19 (1.3)
Cough 19 (1.3) 12 (1.7) 13 (1.8) 25 (1.7)
Oropharyngeal pain 13 (0.9) 10 (1.4) 12 (1.6) 22 (1.5)
Bronchitis 17 (1.2) 9 (1.3) 11 (1.5) 20 (1.4)
Influenza 34 (2.3) 8 (1.1) 20 (2.7) 28 (2.0)
Constipation 8 (0.6) 7 (1.0) 11 (1.5) 18 (1.3)
Migraine 14 (1.0) 7 (1.0) 12 (1.6) 19 (1.3)
  1. Indicates P < .05 compared with placebo
  2. Indicates P < .001 compared with placebo